192 related articles for article (PubMed ID: 37117845)
1. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
Nf L; Ai M
Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
[TBL] [Abstract][Full Text] [Related]
2. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
[TBL] [Abstract][Full Text] [Related]
3. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
4. Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre.
Rak B; Maksymowicz M; Grzywa TM; Sajjad E; Pękul M; Włodarski P; Zieliński G
Endokrynol Pol; 2020; 71(2):116-125. PubMed ID: 32154573
[TBL] [Abstract][Full Text] [Related]
5. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
6. The molecular biology of thyrotroph pituitary neuroendocrine tumors.
Horiguchi K
Endocr J; 2023 Feb; 70(2):135-139. PubMed ID: 36653153
[TBL] [Abstract][Full Text] [Related]
7. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification.
Ho DM; Hsu CY; Ting LT; Chiang H
Histopathology; 2001 Sep; 39(3):310-9. PubMed ID: 11532042
[TBL] [Abstract][Full Text] [Related]
8. Plurihormonal Pit-1 lineage adenoma presenting as meningitis with recurrence after somatostatin analogue.
Olmedilla Y; Khan S; Young V; Joseph R; Cudlip S; Ansgorge O; Grossman A; Pal A
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30897548
[TBL] [Abstract][Full Text] [Related]
9. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor profile in pituitary thyrotroph adenomas.
Thodou E; Kontogeorgos G
Clin Neurol Neurosurg; 2020 Aug; 195():105865. PubMed ID: 32416325
[TBL] [Abstract][Full Text] [Related]
11. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
[TBL] [Abstract][Full Text] [Related]
12. Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.
Andrews JP; Joshi RS; Pereira MP; Oh T; Haddad AF; Pereira KM; Osorio RC; Donohue KC; Peeran Z; Sudhir S; Jain S; Beniwal A; Chopra AS; Sandhu NS; Tihan T; Blevins L; Aghi MK
World Neurosurg; 2021 Jul; 151():e185-e191. PubMed ID: 33862299
[TBL] [Abstract][Full Text] [Related]
13. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
[TBL] [Abstract][Full Text] [Related]
14. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
17. Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation.
Zheng L; Yan X; Hu C; Zhang P; Chen Y; Zheng Q; Hu L; Wang M; Li G; Wu P; Jiang C; Tian J; Zhang S; Wang X
Front Endocrinol (Lausanne); 2022; 13():848762. PubMed ID: 35370935
[TBL] [Abstract][Full Text] [Related]
18. Expression of human Pit-1 product in the human pituitary and pituitary adenomas. Immunohistochemical studies using an antibody against synthetic human Pit-1 product.
Sanno N; Teramoto A; Matsuno A; Osamura RY
Arch Pathol Lab Med; 1996 Jan; 120(1):73-7. PubMed ID: 8554449
[TBL] [Abstract][Full Text] [Related]
19. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
20. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
